The ability of cell and gene therapy companies to raise capital this year will hinge on their ability to address the manufacturing of their products as well as address medical needs beyond cancer, a panel of three investors and an industry executive agreed yesterday. Speaking at the Alliance for Regenerative Medicine (ARM)’s Cell & Gene […]